FDA panel recommends approval of COPD drug from GSK, Theravance

04/18/2013 | Bloomberg Businessweek

An FDA panel recommended approval of GlaxoSmithKline and Theravance's Breo Ellipta dry powder inhaler to address chronic obstructive pulmonary disease. The agency could decide on the drug's approval by May 12.

View Full Article in:

Bloomberg Businessweek

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC